Actinium Pharmaceuticals, Inc. (ATNM) Has The Technology, The Market, And The Connections
Small cap
Seeking Alpha Analyst Since 2010
Actinium Pharmaceuticals, a New York based biopharmaceutical company specializing in the development of cancer drugs, has important connections in both research and industry, and is targeting a major market for which there is currently no approved drug.
In research, Actinium's patented technology was co-developed with Memorial Sloan Kettering Cancer Center (MSKCC), one of the world's most prestigious cancer centers. In addition, Actinium's largest shareholder, AHLB Holdings LLC, is wholly owned by MSKCC. In industry, the company's second largest shareholder is a subsidiary of Merck & Co., one of the largest pharmaceutical companies in the world.
Actinium is focused on treating cancer. Half of all men, and a third of all women, will develop at least one form of cancer during their lifetime. The U.S. alone registers 1.5 million new cancer cases annually, with over 12 million worldwide, and this doesn't include non-melanoma skin cancers. Worldwide sales of biopharmaceutical products for treating cancer are approximately $50 billion per year with U.S. sales being approximately half of that.
Actinium is currently developing blood cancer therapies, built on proprietary Alpha Particle Immunotherapy (OTC:APIT) technology. The company's primary drug candidate, Iomab-B, is for the treatment of acute myeloid leukemia, and is already prepared to enter a pivotal Phase III trial, which may lead to FDA approval. Iomab-B is developed for patients age 55 or older who suffer from acute myeloid leukemia, one of the deadliest of blood cancers for which there are no approved drugs. Another drug, Actimab-A, also for acute myeloid leukemia, is on track to produce Phase I/II interim data in 4Q 2014.
Actinium's market potential is further strengthened by the fact that its highly patented platform technology could be used to target a wide variety of cancers. Preclinical and clinical work has already focused on Non-Hodgkin Lymphoma (NHL), brain cancer, bladder cancer, ovarian cancer, breast cancer, prostate cancer, and a number of other cancer related indications. (Algeta, a company with similar technology, was recently bought by Bayer for $2.4 billion.)
For additional information, visit ActiniumPharmaceuticals.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.